A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

Sex: Male

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 999

Sponsor: Sumitomo Pharma America, Inc.

Summary

This is a multi-center, prospective, observational study of patients being treated with ORGOVYX. The goal of this study is to generate real-world evidence about the safety and effectiveness of ORGOVYX in patients with prostate cancer in routine clinical care and the clinical course during treatment with and following cessation of ORGOVYX.

Eligibility Criteria

Inclusion Criteria: * Patients who are diagnosed with prostate cancer and initiating treatment with ORGOVYX at the time of enrollment or within 1 month prior to enrollment and who remain on treatment at enrollment * Patients who are willing and able to complete PRO assessments during the study * Patients who have reviewed and signed the informed consent form (ICF) Exclusion Criteria: * Patients with a history of surgical castration * Patients with a medical or psychiatric condition that precludes participation in the opinion of the treating physician * Patients whose original treatment plan is intended to be less than a total of 4 months of ORGOVYX

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05467176). StuddyBuddy aggregates publicly available trial information.